Using epigenetic modifiers to treat retinal degeneration
Epigenetic Modifiers to treat Photoreceptor Degenerations
This study is exploring new eye treatments for people with Retinitis Pigmentosa that could help protect vision by using special drugs applied directly to the eye, aiming to improve how well you see and how well you can distinguish between different shades.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Skyran Biologics, INC. NIH-funded |
| Lab location | 1 site (Harrisburg, UNITED STATES) |
| Project ID | NIH-10693776 on NIH RePORTER |
What this research studies
This research focuses on developing topical treatments to combat retinal degenerative diseases, particularly Retinitis Pigmentosa. The approach involves using epigenetic modifiers that can reverse chromatin condensation, allowing photoreceptors to survive disease stresses. The researchers aim to deliver these drugs directly to the eye to minimize systemic side effects while preserving normal cell function. The study also investigates the effectiveness of these treatments in improving visual acuity and contrast sensitivity.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with retinal degenerative diseases, such as Retinitis Pigmentosa.
Not a fit: Patients with retinal conditions not related to degeneration or those with advanced stages of retinal disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option for patients suffering from retinal degenerative diseases, potentially improving their vision and quality of life.
How similar studies have performed: Previous research has shown promise in using epigenetic modifiers for similar conditions, indicating potential for success in this innovative approach.
Where this research is happening
Harrisburg, UNITED STATES
- Skyran Biologics, INC. — Harrisburg, United States (Active)
Researchers
- Principal investigator: Tombran-Tink, Joyce — Skyran Biologics, INC.
- Study coordinator: Tombran-Tink, Joyce
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.